These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39251782)

  • 1. Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection.
    Li X; Song D; Hao Y; Ren M; Guo Y; Zhao H; Wang Y; Tang L
    Sci Rep; 2024 Sep; 14(1):20981. PubMed ID: 39251782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
    Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
    BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
    Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
    Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features and outcomes of PLA2R-related membranous nephropathy with renal glycosuria.
    Zhang P; Xu F; Liu X; Hu Z; Liang D; Liang S; Zhu X; Yang F; Zeng C
    Clin Nephrol; 2024 Nov; 102(5):273-284. PubMed ID: 39099383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of efficacy and safety of immunosuppressive therapy and rituximab targeting therapy in idiopathic membranous nephropathy].
    Zhao R; Fan R; Pan Y; Guo Y; Han Y; Wang Y; Zhang J; Yang H; Yu D; Chen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jul; 40(7):636-641. PubMed ID: 39179407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
    Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
    Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
    Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
    PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
    Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
    Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
    Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
    J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus-like membranous nephropathy during the postpartum period expressing glomerular antigens exostosin 1/exostosin 2 and phospholipase A2 receptor: a case report.
    Miyasaka R; Wada Y; Takeuchi K; Abe T; Uchitsubo R; Kawamura S; Sakurabayashi S; Naito S; Aoyama T; Shimizu A; Takeuchi Y
    CEN Case Rep; 2024 Oct; 13(5):318-325. PubMed ID: 38280123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis.
    Song D; Guo Y; Wang Y; Tang L
    Int Immunopharmacol; 2024 Sep; 139():112731. PubMed ID: 39068756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.